EUVIMEDSkopri EUVIMED
Multizentrische StudieBeobachtungsstudieOpen access · CC BY-NC 4.0

Adolescent‐ and adult‐onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020

Orlane Magnier iD, Isabelle Schiff, Justine Cristante, Olivier Chabre, Melanie Veloso, Jean-Luc Bosson, Anne-Sophie Defachelles iD, Camille Cordero, Christine Do Cao, Estelle Thebaud, Delphine Drui, Pablo Berlanga iD and 14 more

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31074 ↗

At a glance

Multizentrische Studie in Pediatric Blood & Cancer, 2024. Written by Orlane Magnier and 25 co-authors. Institution: Cancer and Blood Diseases Department, Medical Oncology, Grenoble Alpes University Hospital, Grenoble, France. Major MEDLINE topics: Neuroblastoma. Cited 5 times so far (Crossref); 54 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Association Grenobloise de Développement d'Etudes et Recherches en Médecine Infantile (AGDERMI).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Adult‐ and adolescent‐onset neuroblastomas are rare, with no established therapy. In addition, rare pheochromocytomas may harbor neuroblastic components. This study was designed to collect epidemiological, diagnostic and therapeutic data in order to better define the characteristics of malignant peripheral neuroblastic tumors (MPNT) and composite pheochromocytomas (CP) with MPNT. Procedure Fifty‐nine adults and adolescents (aged over 15 years) diagnosed with a peripheral or composite neuroblastic tumor, who were treated in one of 17 institutions between 2000 and 2020, were retrospectively studied.

Results

Eighteen patients with neuroblastoma (NB) or ganglioneuroblastoma (GNB) had locoregional disease, and 28 patients had metastatic stage 4 NB. Among the 13 patients with CP, 12 had locoregional disease. Fifty‐eight percent of the population were adolescents and young adults under 24 years of age. The probability of 5‐year event‐free survival (EFS) was 40% (confidence interval: 27%–53%).

Conclusions

Outcomes were better for patients with localized tumor than for patients with metastases. For patients with localized tumor, in terms of survival, surgical treatment was the best therapeutic option. Multimodal treatment with chemotherapy, surgery, radiotherapy, and immunotherapy‐based maintenance allowed long‐term survival for some patients. Adolescent‐ and adult‐onset neuroblastoma appeared to have specific characteristics associated with poorer outcomes compared to pediatric neuroblastoma. Nevertheless, complete disease control improved survival. The presence of a neuroblastic component in pheochromocytoma should be considered when making therapeutic management decisions. The development of specific tools/resources (Tumor Referral Board, Registry, biology, and trials with new agents or strategies) may help to improve outcomes for patients.

Subjects

MeSH terms (MEDLINE)

NeuroblastomaHumansRetrospective StudiesAdolescentMaleFemaleAdultYoung AdultFranceSurvival RateMiddle AgedAdrenal Gland NeoplasmsPheochromocytomaFollow-Up StudiesCombined Modality TherapyPrognosisAge of OnsetGanglioneuroblastomaAged

Author keywords

adolescent and young adult canceradult‐onset pediatric cancerganglioneuroblastomaneuroblastomaperipheral neuroblastic tumorpheochromocytoma

Authors and institutions

  • Cancer and Blood Diseases Department, Medical Oncology, Grenoble Alpes University Hospital, Grenoble, France.
  • Pediatric Oncology and Hematology Department, Grenoble Alpes University, Grenoble, France.
  • Endocrinology Department, Grenoble Alpes University, Grenoble, France.
  • Public Health and Biostatistics, Grenoble Alpes University Hospital, Grenoble, France.
  • Pediatric and AYA Oncology Department, Oscar Lambret Center, Lille, France.
  • Pediatric Oncology Department, Curie Institute, Paris, France.

ORCID profiles: Orlane Magnier, Anne-Sophie Defachelles, Pablo Berlanga

Funding

  • Association Grenobloise de Développement d'Etudes et Recherches en Médecine Infantile (AGDERMI)

Cite

APA

Magnier, O., Schiff, I., Cristante, J., Chabre, O., Veloso, M., Bosson, J. L., Defachelles, A. S., Cordero, C., Do Cao, C., Thebaud, E., Drui, D., Berlanga, P., Dumont, B., Chastagner, P., Tandonnet, J., Gambart, M., Jannier, S., Pluchart, C., Andry, L., …, & Plantaz, D. (2024). Adolescent‐ and adult‐onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31074

Vancouver

Magnier O, Schiff I, Cristante J, Chabre O, Veloso M, Bosson JL, et al. Adolescent‐ and adult‐onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31074

BibTeX
@article{Magnier2024,
  author = {Magnier, Orlane and Schiff, Isabelle and Cristante, Justine and Chabre, Olivier and Veloso, Melanie and Bosson, Jean-Luc and Defachelles, Anne-Sophie and Cordero, Camille and Do Cao, Christine and Thebaud, Estelle and Drui, Delphine and Berlanga, Pablo and Dumont, Benoit and Chastagner, Philippe and Tandonnet, Julie and Gambart, Marion and Jannier, Sarah and Pluchart, Claire and Andry, Leslie and Laithier, Véronique and Klein, Sébastien and Carausu, Liana and Akbaraly, Tasmine and Probert, Jamie and Habert-Dantigny, Raphaelle and Plantaz, Dominique},
  title = {Adolescent‐ and adult‐onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31074}
}
Start for free →